Overview

A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis

Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
An extension study to evaluate the long-term safety, tolerability and efficacy of GW-1000-02 treatment in multiple sclerosis.
Phase:
Phase 3
Details
Lead Sponsor:
GW Pharmaceuticals Ltd.
Treatments:
Dronabinol
Nabiximols